Literature DB >> 30688135

Pregabalin as Adjunctive Treatment for Focal Onset Seizures in Pediatric Patients: A Randomized Controlled Trial.

Jeremias Antinew1, Bruno Pitrosky2,3, Lloyd Knapp1, Mary Almas4, Verne Pitman1, Jing Liu1, Dana Craiu5, Margaret Modequillo6, Douglas Nordli7, Viktor Farkas8, Mark Kristof Farkas8.   

Abstract

Efficacy and safety of pregabalin as adjunctive treatment for children (aged 4-16 years) with partial-onset seizures, hereafter termed focal onset seizures for this study, was evaluated. This double-blind, randomized, placebo-controlled, international study had 3 phases: 8-week baseline, 12-week double-blind treatment (2-week dose escalation; 10-week fixed dose), and 1-week taper. Selection criteria included experiencing focal onset seizures and receiving a stable regimen of 1 to 3 antiepileptic drugs. Study treatments were pregabalin 2.5 mg/kg/d, 10 mg/kg/d, or placebo; doses were increased to 3.5 or 14 mg/kg/d for subjects weighing <30 kg. The key endpoints were change in loge(28-day seizure rate), achieving a ≥50% seizure responder rate, safety, and tolerability during double-blind treatment. Subjects (n = 295; mean age 10.2 years, 55% male, 69% white) were randomized to pregabalin 2.5 mg/kg/d (n = 104), 10 mg/kg/d (n = 97), or placebo (n = 94). A statistically significant reduction in loge(28-day seizure rate) was demonstrated with pregabalin 10 mg/kg/d (a 19.9% improvement over placebo; P = .0185). Seizure frequency was numerically improved (statistically nonsignificant) with pregabalin 2.5 mg/kg/d ( P = .2577). Responder rate significantly favored pregabalin 10 mg/kg/d (40.6%, P = .0068) compared with placebo (22.6%) and was numerically improved with pregabalin 2.5 mg/kg/d (29.1%, P = .2600). Common adverse events (≥10% of any group) in 10 mg/kg/d, 2.5 mg/kg/d, and placebo groups, respectively, included somnolence (25.8%, 17.3%, 13.8%), increased weight (13.4%, 3.8%, 4.3%), and increased appetite (10.3%, 6.7%, 4.3%). Pregabalin 10 mg/kg/d demonstrated efficacy in seizure frequency reduction in children with focal onset seizures compared with placebo, and both pregabalin doses were generally safe and well tolerated. www.clinicialtrials.gov identifier NCT01389596; EudraCT #2010-020852-79.

Entities:  

Keywords:  children; focal onset seizures; pediatric; pregabalin

Mesh:

Substances:

Year:  2019        PMID: 30688135     DOI: 10.1177/0883073818821035

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  4 in total

Review 1.  Neurocognitive Effects of Antiseizure Medications in Children and Adolescents with Epilepsy.

Authors:  Frank M C Besag; Michael J Vasey
Journal:  Paediatr Drugs       Date:  2021-05-06       Impact factor: 3.022

Review 2.  Impact of Antiseizure Medications on Appetite and Weight in Children.

Authors:  Ersida Buraniqi; Hicham Dabaja; Elaine C Wirrell
Journal:  Paediatr Drugs       Date:  2022-05-21       Impact factor: 3.022

Review 3.  Pregabalin add-on for drug-resistant focal epilepsy.

Authors:  Mariangela Panebianco; Rebecca Bresnahan; Anthony G Marson
Journal:  Cochrane Database Syst Rev       Date:  2022-03-29

4.  Pregabalin as adjunctive therapy in adult and pediatric patients with generalized tonic-clonic seizures: A randomized, placebo-controlled trial.

Authors:  Joseph Driscoll; Mary Almas; Gabriela Gregorian; Alla Kyrychenko; Iryna Makedonska; Jing Liu; Jeffrey Patrick; Joseph M Scavone; Jeremias Antinew
Journal:  Epilepsia Open       Date:  2021-05-16
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.